603077 和邦生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,999,261-16.51%8,824,10813,038,9489,987,3545,260,766
减:营业总成本1,944,3271.40%7,325,6298,554,8506,435,6694,861,695
    其中:营业成本1,797,1371.56%6,771,5707,451,3155,854,7274,271,965
               财务费用4,253-13.02%(32,503)24,12684,400120,712
               资产减值损失----(36,752)(80,828)--(5,979)
公允价值变动收益------------
投资收益(736)-111.47%75,21921,83126,95124,376
    其中:对联营企业和合营企业的投资收益----51,22319,67012,8029,037
营业利润43,612-90.86%1,541,7924,481,1573,591,076440,493
利润总额43,609-90.85%1,535,9664,478,5623,578,38015,809
减:所得税费用16,465-82.69%257,266668,323551,87912,900
净利润27,143-92.88%1,278,6993,810,2393,026,5022,910
减:非控股权益(2,649)-82.46%(4,545)3,4308,031(38,033)
股东净利润29,793-92.49%1,283,2443,806,8093,018,47140,942

市场价值指针
每股收益 (元) *0.004-92.09%0.1470.4380.3580.005
每股派息 (元) *------0.0450.015--
每股净资产 (元) *2.155-2.60%2.2172.1651.6131.262
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容